S2050 SATB1 Influences Expression of Cytokines in Colorectal Cell Lines and Is Associated with a More Aggressive Phenotype

Rygiel, Agnieszka Magdalena; Davelaar, Akueni L.; Milano, Francesca; Fockens, Paul; Krishnadath, Kausilia K.

doi:10.1016/s0016-5085(09)61465-7

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SATB1 exhibits specific epigenetic modifications at target gene loci, directly upregulating metastasis-associated genes while downregulating tumor-suppressor genes. Moreover, investigators found SATB1 to be expressed in a number of other cancer cells, such as gastric cancer, colorectal cancer and laryngeal carcinoma cells, and it appears to be associated with an aggressive phenotype (11)(12)(13)(14). Accumulating evidence has shown that SATB1: a) correlates with a high expression of tumor necrosis factor (TNF)-α, which mediates the inflammatory processes in tumor invasion, angiogenesis and metastasis; b) affects the expression of anti-inflammatory interleukins (IL)-4 and IL-10, which in turn are known to lead to escape from cancer immune surveillance; and c) is significant in anti-apoptotic activity (15)(16).…”

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma

Xiang

Zhou

et al. 2012

Oncol Lett

View full text Add to dashboard Cite

Abstract. Special AT-rich sequence binding protein 1 (SATB1) is a master chromatin organizer that has recently been reported to directly upregulate metastasis-associated genes and downregulate tumor suppressor genes. However, its clinical significance in the case of ovarian cancer remains unclear. In the current study, we assessed the expression levels of SATB1 in ovarian cancer and aimed to show whether it may be a conventional clinicopathological parameter. Epithelial ovarian cancer (n=91), borderline cystadenoma (n=13) and normal ovarian background tissues (n=8) were collected immediately following excision during surgery. The mRNA expression levels of SATB1, VEGF-A and MMP-9 were determined using real-time quantitative PCR. Western blotting and immunohistochemical staining were carried out to detect the protein expression levels of SATB1. Expression levels within the ovarian cancer specimens were compared to the normal background tissues and analyzed against FIGO stage, lymph node involvement and histological type. SATB1 mRNA in malignant and borderline ovarian cystadenoma tissues was 6.74-and 5.70-fold higher compared with normal ovarian tissue, respectively (P<0.01). Western blot analysis revealed that a strong positive band of SATB1 expression was present in ovarian cancer tissues. Immunohistochemical staining showed that the positive expression rates of SATB1 in ovarian cancer, borderline ovarian cystadenoma and normal ovarian tissues were 69.2, 61.5 and 0% (P<0.01), respectively. SATB1 expression increased concomitantly with increasing FIGO stage and lymph node involvement. Survival curves showed that a higher SATB1 expression was correlated with shorter survival. Our results provide evidence that SATB1 expression is significantly associated with progression, metastasis and prognosis of epithelial ovarian cancer. SATB1 may therefore serve as a conventional clinicopathological parameter of ovarian cancer. IntroductionOvarian cancer remains the leading cause of mortality from gynecological malignancies (1), due to its insidious symptoms, high incidence of metastasis and high relapse rate. At the time of diagnosis, up to 60% of cases present at an advanced stage with a low 5-year relative survival rate of approximately 30% (2) and metastasis has already occurred (3). Lymph node metastasis, which was thought to appear at advanced stages, has been demonstrated to show 10-30% incidence even at early stages. Patients with negative nodes survived significantly longer than those who had node metastases (4). Therefore, lymphatic metastasis was verified to be a strong indicator of poor prognoses and may account for the majority of ovarian cancer-related deaths (5-9). For the last decade, little was known about the major molecular mechanisms in terms of how genes facilitate metastasis, and this phenomenon is just beginning to be elucidated.Recently, there has been a marked increase in studies of the activities of special AT-rich sequence binding protein 1 (SATB1) in oncogene regulation. Early on, SATB1 was identifi...

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma

Xiang

Zhou

et al. 2012

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…(4)(5)(6) Silencing of SATB1 mimics the effects of interferon (IFN)-c treatment on the chromatin loop architecture of the MHC class I locus and alters the expression of genes within the locus. (5) Besides the immune system, SATB1 is also expressed in many cancer cells, such as colorectal cancer cells, (7) lymphoma cells, (8) and breast cancer cells. (9) SATB1 has now revealed a darker side.…”

mentioning

confidence: 99%

“…Rygiel et al found that SATB1 expression in colorectal cancer seems to be associated with an aggressive phenotype. (7) SATB1 correlates with high expression of tumor necrosis factor (TNF)-a, which mediates the inflammatory processes in tumor invasion, angiogenesis, and metastasis. On the other hand, SATB1 influences the expression of anti-inflammatory interleukin (IL)-4 and IL-10, which in turn are known to lead to escape from cancer immune surveillance.…”

mentioning

confidence: 99%

Overexpression and involvement of special AT‐rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells

Chen

et al. 2009

Cancer Science

View full text Add to dashboard Cite

Special AT-rich sequence binding protein (SATB) 1 has been proposed to act as a determinant for the acquisition of metastatic activity by controlling expression of a specific set of genes that promote metastatic activity. Here we found that SATB1 expression is upregulated in multidrug-resistant breast cancer cells that exhibit higher invasive potential than the parental cells. Apart from accelerating metastasis and inducing epithelial-mesenchymal transition, SATB1 was demonstrated to confer resistance to both P-glycoprotein-related and P-glycoprotein-non-related drugs on MCF7 cells, which was accompanied by decreasing accumulation of adriamycin in SATB1-overexpressing transfectants. SATB1 depletion could partially reverse the multidrug resistance (MDR) phenotype of MCF7 ⁄ ADR in vitro and in vivo. The SATB1-induced P-glycoprotein-mediated MDR could be reversed by treatment with anti-Pglycoprotein mAb. Moreover, SATB1 plays an important role in anti-apoptotic activity in MCF7 ⁄ ADR cells in response to adriamycin treatment, which suggests another mechanism contributing to SATB1-related MDR of breast cancers. These data provide new insights into the mode by which breast tumors acquire the MDR phenotype and also imply a role for SATB1 in this process. (Cancer Sci 2010; 101: 80-86) S pecial AT-rich sequence binding protein (SATB) 1, the global chromatin organizer and transcription factor, has emerged as a key factor in regulating gene expression during the differentiation and activation of T cells, making it a key player in the immune system.(1) Previous studies have unraveled the role of SATB1 in the organization of the chromatin ''loopscape'' and its dynamic nature in response to physiological stimuli. At the genome-wide level, SATB1 seems to play a role in the organization of the transcriptionally poised chromatin. (2,3) SATB1 organizes the MHC class I locus into distinct chromatin loops by tethering matrix association regions to the nuclear matrix at fixed distances.(4-6) Silencing of SATB1 mimics the effects of interferon (IFN)-c treatment on the chromatin loop architecture of the MHC class I locus and alters the expression of genes within the locus. Besides the immune system, SATB1 is also expressed in many cancer cells, such as colorectal cancer cells,lymphoma cells, (8) and breast cancer cells. (9) SATB1 has now revealed a darker side. Rygiel et al. found that SATB1 expression in colorectal cancer seems to be associated with an aggressive phenotype.(7) SATB1 correlates with high expression of tumor necrosis factor (TNF)-a, which mediates the inflammatory processes in tumor invasion, angiogenesis, and metastasis. On the other hand, SATB1 influences the expression of anti-inflammatory interleukin (IL)-4 and IL-10, which in turn are known to lead to escape from cancer immune surveillance. In addition, SATB1 is also an essential contributing factor in the most aggressive forms of breast cancer.(9) By introducing SATB1 into otherwise non-metastatic breast cancer cells, invasive tumors can be induced in mice; ...

show abstract

S2050 SATB1 Influences Expression of Cytokines in Colorectal Cell Lines and Is Associated with a More Aggressive Phenotype

Cited by 2 publications

References 0 publications

AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma

AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma

Overexpression and involvement of special AT‐rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells

Contact Info

Product

Resources

About